Prime Medicine, Inc. (PRME) Q3 2026 earnings results

Prime Medicine, Inc. (PRME) reported Q3 2026 results on Nov 12, 2026, 4:05:46 PM ET: GAAP EPS -$0.22 vs. -$0.24 expected (beat by 8.0%); revenue $4.21M vs. $1.08M expected (beat by 290.9%), according to Nexqual's capture of the SEC 8-K filing (nexqual.com/earnings/2026-11-12/PRME). Outlook: The company expects its current cash and proceeds from its November 2026 offering to fund operations through 2027.

PRME Q3 2026 results vs. estimates, Nexqual · nexqual.com/earnings/2026-11-12/PRME
MetricReportedAnalyst estimateResult
EPS (GAAP, diluted)-$0.22-$0.24Beat by 8.0%
Revenue$4.21M$1.08MBeat by 290.9%

Analyst estimate: the average forecast before the release.

Source

Figures from the SEC 8-K filing, released Nov 12, 2026, 4:05:46 PM ET. Nexqual published them 95 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.

Year over year

Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): GAAP diluted EPS was -$0.22 vs. -$0.32 (+31.3%).

Stock reaction

The results came out after the market closed. PRME closed at $4.27 on November 13, 2026, up 9.8% from its $3.89 close on November 12, 2026 before the results. Latest: $3.89 as of 3:49 PM ET, +0.1% since the pre-release close.

Questions and answers

Did Prime Medicine, Inc. beat earnings expectations?

Yes. Prime Medicine, Inc. reported GAAP EPS of -$0.22 against an average analyst estimate of -$0.24 (beat by 8.0%), and revenue of $4.21M against $1.08M expected (beat by 290.9%). Source: Nexqual (nexqual.com/earnings/2026-11-12/PRME).

What were Prime Medicine, Inc.'s Q3 2026 earnings and revenue?

GAAP diluted EPS of -$0.22 and revenue of $4.21M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): GAAP diluted EPS was -$0.22 vs. -$0.32 (+31.3%). Source: Nexqual (nexqual.com/earnings/2026-11-12/PRME).

When did Prime Medicine, Inc. report Q3 2026 earnings?

Nov 12, 2026, 4:05:46 PM ET, in an SEC 8-K filing (Item 2.02). Source: Nexqual (nexqual.com/earnings/2026-11-12/PRME).

How did PRME stock react to the earnings?

The results came out after the market closed. PRME closed at $4.27 on November 13, 2026, up 9.8% from its $3.89 close on November 12, 2026 before the results. Latest: $3.89 as of 3:49 PM ET, +0.1% since the pre-release close. Source: Nexqual (nexqual.com/earnings/2026-11-12/PRME).

What did Prime Medicine, Inc. say about its outlook?

The company expects its current cash and proceeds from its November 2026 offering to fund operations through 2027. Source: Nexqual (nexqual.com/earnings/2026-11-12/PRME).

More on PRME

PRME stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 12, 2026.

Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 18, 2026 at 20:49 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 18, 2026 at 20:49 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt